Healthcare
Foghorn Therapeutics Inc.(FHTX)
Live Price
Offline$4.15
+2.47% today
1Y Change
-15.31%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $270.00M
- Revenue Growth
- +36.8%
- EPS Growth
- +25.3%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Foghorn Therapeutics Inc. (FHTX) is a Healthcare stock with a market cap of $270.00M and listed on NASDAQ. The stock last traded around $4.15 and down 15.3% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +36.8%, EPS growth of +25.3%, a dividend yield of 0.0%. What stands out right now is revenue +36.8%, EPS +25.3%, free cash flow +15.0% with operating margin -265.6% and ROIC -58.9%. Valuation already assumes a fairly strong business story at price/sales 8.9. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines FHTX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+36.8% vs +7.6% peer median
Operating Margin
Below sector median
-265.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +36.8% and EPS at +25.3%, with operating margin around -265.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -1.5% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | -3.1% | -4.1% | -2.6% |
2026 Mar 11, 2026 | -21.4% | -12.9% | -13.6% | -15.2% |
2025 Nov 5, 2025 | +19.4% | +0.0% | +13.3% | +14.5% |
Benchmark Edge
FHTX vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
FHTX
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
FHTX Max Drawdown
-46.11%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for FHTX and SPY.
Company Overview
Foghorn Therapeutics Inc.
NASDAQ Global Market
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
- Leadership
- Adrian H. Gottschalk
- IPO Date
- Oct 23, 2020
- Employees
- 112
- Street Address
- 500 Technology Square
- Mailing
- Cambridge, MA, 02139
- Region
- Cambridge, MA, US
- Reporting Currency
- USD
- Investor Line
- 617 586 3100
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 8.9
- Price/Book
- โ
Growth
- Revenue
- +36.8%
- EPS
- +25.3%
- Free Cash Flow
- +15.0%
Profitability
- Gross Margin
- 29.8%
- Operating Margin
- -265.6%
- Net Margin
- -240.3%
- ROE
- 88.3%
- ROIC
- -58.9%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 2.73
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.